Abstract:Objective To investigate the characteristics and the frequencies of B cell subsets in peripheral blood of rheumatoid arthritis (RA) patients,and to study the correlation between B cell subsets and clinical indices and influence of different therapies on B cell subsets to deeply understand the pathogenesis of RA.Methods Peripheral blood witched memory B cells,non-switched memory B cells,naive B cells,and double negative B cells of 141 patients and 33 healthy controls were measured by flow cytometry.Patients were divided into three groups based on their therapeutic regimen,including tumor necrosis factor-or (TNF-α) inhibitors combined with disease modifying antirheumatic drugs (DMARDs),DMARDs only and patients without any therapy.The relevance between B cells subsets and clinical manifestations,lab test results exemption were assessed as well as the influence of different therapies.All data were were analyzed by Statistical product and service solutions (SPSS) 23.0 statistical analysis for unpaired t test,analysis of variance and Spearman's correlations analysis.Results ① New-onset RA patients with less than 12 weeks disease duration and never accepted any drugs had a significantly lower frequency of peripheral blood memory B cells,including non-switched memory B cells [(8 ±4)％ vs (13 ±4)％,P＜0.05,t =3.3)] and switched memory B cells [(18±10)％ vs (23±7)％,P＜0.05,t=2.2)],than healthy individuals.② There was a negative association between non-switched memory B cells and disease activity score in 28 joints (r=-0.23,P＜0.05).③ Negative association between non-switched memory B cells and erythrocyte sedimentation rate (ESR),lgG was found,while therewas no association between pre-switched B cells and other laboratory test results.④ Non-switched memory B cells and switched memory B cells increased after TNF-α arntagonist or DMARDs therapy.Conclusion The results of this study suggest that B cell abnormalities in new-onset RA patients with short disease duration are reduced non-switched memory B cells and switched memory B cells.A negative correlation has been found between non-switched memory B cells and ESR and lgG.B cells subsets frequency are changed by TNF-α antagonist and DMARDs,which suggests that changes of B cell subsets may contribute to the occurrence and development of RA.

Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response

Translational Mini‐Review Series on B Cell‐Directed Therapies: The pathogenic role of B cells in autoantibody‐associated autoimmune diseases – lessons from B cell‐depletion therapy

The quest for personalized B-cell depletion therapy in rheumatic disease

How does B cell depletion therapy work, and how can it be improved?

Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire

Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis

B cell depletion therapies in autoimmune disease: advances and mechanistic insights

Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis

A new perspective on therapies involving B-cell depletion in autoimmune diseases

Disturbance of peripheral blood B cells homeostasis in rheumatoid arthritis and the influence of therapy on B cells homeostasis

B cell depletion attenuates CD27 signaling of T helper cells in multiple sclerosis

Abatacept Reduces Levels of Switched Memory B Cells, Autoantibodies, and Immunoglobulins in Patients with Rheumatoid Arthritis

B-Cell Depletion and Repopulation in Autoimmune Diseases

Characterization of T-Cell Receptor Repertoire in Patients with Rheumatoid Arthritis Receiving Biologic Therapies

Age-associated B cells in early drug-naive rheumatoid arthritis patients

High Frequencies of Activated B Cells and T Follicular Helper Cells Are Correlated with Disease Activity in Patients with New-Onset Rheumatoid Arthritis.

Autoreactive B cells remain active despite clinical disease control in rheumatoid arthritis

Professional antigen‐presenting Tbet+CD11c+ B cells correlate with bone destruction in untreated rheumatoid arthritis

Non-depleting Down-Modulation of Human B-cells Through Inhibitory Coupling of FcγRIIB (CD32B) and the BCR with Bi-Specific DART Molecules with Extended Pharmacokinetics. (51.8)

The Dual Effects of B Cell Depletion on Antigen-Specific T Cells in BDC2.5NOD Mice

Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy